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Abstract  
Introduction/background: Retinoblastoma, uveal and conjunctival melanomas are important 
malignancies within the remit of ocular oncology. Outlined are the diagnostic features and 
management principles, as well as advancements in the field and current challenges.  
Sources of data: Original papers, reviews and guidelines.  
Areas of agreement: Most eyes with retinoblastoma (International Intraocular Retinoblastoma 
Classification (IIRC) group A-D) are salvaged, whereas advanced cases (group E) remain a challenge. 
Despite a high rate of local tumour control in uveal melanoma, metastatic spread commonly occurs. 
Conjunctival melanoma is treated by complete resection, but high rates of local recurrence occur, with 
the possibility of systemic relapse and death.  
Areas of controversy: Use of the IIRC in retinoblastoma, and systemic screening in melanomas.  
Growing points: Utilization of novel treatment modalities in retinoblastoma and an increasing 
understanding of the genetic basis of melanomas.  
Areas timely for developing research: Improvements in chemotherapy delivery in retinoblastoma 
and prognostic tests in melanomas.  
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Introduction 
Tumours of the eye comprise intraocular, ocular surface, orbital and adnexal lesions. In this review, 
we concentrate on the intraocular cancers retinoblastoma and uveal melanoma, and on the ocular 
surface cancer conjunctival melanoma. These are rare compared to non-ocular malignancies, but are 
an important branch of ophthalmology, within the subspecialty of ocular oncology.  
Retinoblastoma is the most common intraocular malignancy of childhood worldwide, with 
approximately 50-60 new cases per year in the UK and 300-400 in the USA. A variety of treatments 
are employed to combat retinoblastoma and these are highlighted, including novel modes of delivery. 
There are challenges in treating advanced intraocular retinoblastoma and controversies in the current 
International Classification.  
Uveal melanoma is the most common primary intraocular malignancy in adults worldwide. In the UK, 
approximately 500-600 new cases are diagnosed each year. There has been much recent work on 
prognostication genetics, to identify those at high risk of metastatic spread. Screening for systemic 
relapse, usually in the liver, following control of the primary intraocular tumour, varies with no 
consensus for the preferred modality or frequency.  
Conjunctival melanoma is a potentially fatal malignancy. It is considered rare, even in terms of ocular 
tumours, but thought to be increasing in incidence. Current management involves surgical resection, 
but emerging areas include the role of sentinel lymph node biopsy, genetic studies as prognostic 
factors and potential treatment targets.  
 
Retinoblastoma	
Introduction 
Retinoblastoma, the most common intraocular cancer in children, occurring in approximately 1 in 
18,000 live births, is a disorder initiated in the majority of cases by mutation of the RB1 gene.1 The 
cancer, which is thought to originate in a photoreceptor precursor cell, develops in early childhood, 
may be heritable or non-heritable, and involves one or both eyes. Nearly 3% of unilateral non-
heritable retinoblastoma cases lack the RB1 mutations, however show high-level of MYCN oncogene 
amplification.2 Intracranial involvement, mainly of the pineal gland, known as trilateral 
retinoblastoma, occurs in less than 5% of inherited cases, and has decreased in the era of intravenous 
chemotherapy for intraocular disease. Untreated retinoblastoma is generally fatal by spread to the 
central nervous system (via the optic nerve) and haematogenous spread. However, rare cases of 
spontaneous regression are known to exist. A “white pupillary reflex” and strabismus are the most 
common presenting symptoms. In developed countries the prognosis for children with retinoblastoma 
is good, with 5-year survival rates greater than 95%. In countries without established specialist 
centres, primary care infrastructure and educational strategies, the survival rate can be as low as 20%.  
Paradigm shift and reclassification 
Early diagnosis and treatment of intraocular retinoblastoma are key features in combating the disease. 
New treatment modalities have evolved and currently a wide armamentarium is available to treat 
various manifestations of intraocular retinoblastoma. In the majority of the 20th century the main 
conservative treatment modality was external beam radiotherapy (EBRT) but was associated with an 
increased risk of cancers in patients with genetic retinoblastoma.3 Currently EBRT is used to salvage 
eyes failing other treatments,4 but is regarded by many authorities as tantamount to treatment failure. 
Systemic chemotherapy (“chemoreduction”) supplanted EBRT as the main treatment for intraocular 
retinoblastoma in the 1990s after initial work in London, UK. This shift from radiotherapy to 
chemotherapy required a reclassification of intraocular disease from the Reese-Ellsworth 
classification,5 which predicted the globe salvage after EBRT to the International Intraocular 
Retinoblastoma Classification (IIRC), which was more relevant to chemotherapy outcomes.6 Eyes 
manifesting the tumour were classified into 5 groups from A to E (Figure 1) according to size, 
presence and extent of tumour seeds (vitreous or sub-retinal), and development of secondary 
complications (e.g. neovascular glaucoma). The disadvantages have included the inability to use 
historical EBRT outcomes to compare against emerging treatments and the fact that several versions 
of the IIRC have emerged. There is some variation in the definition of tumours in groups B and C, but 
mainly in respect to groups D and E eyes.7 These discrepancies were thought to affect the prognostic 
value of the IIRC, leading to both over- and undertreatment.8  
Management 
IIRC Group A eyes are often amenable to treatment by focal methods, such as cryotherapy or laser 
therapy, with very high success rate. Groups B, C and D eyes are treated in many centres with 
systemic chemotherapy, with or without additional focal consolidating treatments (plaque 
radiotherapy in addition to the abovementioned).9 Chemotherapy is best given according to a 
scheduled intense protocol. The most commonly used drugs include carboplatin, etoposide, and 
vincristine given every 3 weeks through central venous access line, although variations exist with 
number of drugs and cycles used and in the use of additional cyclosporine.10 Globe salvage with 
chemotherapy is achieved in 100% of group A, 93% of group B, 90% of group C, and 47% of group 
D cases.9 Systemic chemotherapy can treat potential metastases, reduces the risk of second non-ocular 
cancers compared to radiotherapy,11  improves visual acuity,12 and presumably reduces 
pinealoblastoma formation.13 In regard to the latter, it is not clear whether intravenous chemotherapy 
is the sole factor responsible for this beneficial effect, the lack of radiotherapy or a combination of 
both.  
Most advanced intraocular retinoblastoma, or group E eyes, are enucleated (removal of the eye). 
Prompt surgery is usually advised.  Giving a trial of chemotherapy prior to enucleation may mask pre-
existing pathologic adverse factors that would have necessitated post-operative adjuvant 
chemotherapy. In a retrospective analysis by Zhao et al., none of 37 group E patients that underwent 
primary enucleation died, but 4 out of 45 group E patients that received chemotherapy prior to 
enucleation died.14 Advanced bilateral group E retinoblastoma, or patients in whom one eye is already 
enucleated and the fellow eye cannot be controlled by conservative means, are very challenging cases 
and no consensus exists regarding their management. While some centres would perform bilateral 
enucleations, in some chemotherapy with or without EBRT would be the treatment of choice.15  
Novel treatments for intraocular retinoblastoma 
With improved survival rates in developed countries, there has been an impetus to treat 
retinoblastoma without removal of the eye and to preserve vision. Advances in ocular drug delivery 
over the last 10 years are revolutionising this cancer– recent developments have delivered 
chemotherapy into the ophthalmic artery or directly into the vitreous cavity.  
Local treatment of retinoblastoma with chemotherapy is an attractive idea to avoid potential systemic 
complications, such as neutropaenic sepsis or cumulative organ toxicities. In 2004, Yamane et al. 
described a system of selective ophthalmic arterial infusion of melphalan to treat intraocular 
retinoblastoma.16 In 2006, Abramson and colleagues modified the Japanese approach by using direct 
intra-ophthalmic artery catheterisation (IAC) in patients with advanced retinoblastoma.17 Reported 
results were encouraging with high eye salvage rates and acceptable side effect profile. Indications for 
use soon expanded for IAC to be utilized as primary and salvage treatments,18 and additional 
chemotherapeutic agents were added to include melphalan, topotecan and carboplatin.19 Some centres 
abandoned the use of systemic chemotherapy as first line therapy for retinoblastoma in favour for 
IAC. Where the tumour burden is mainly retinal or subretinal, there is no doubt that this is a very 
effective treatment. Initial enthusiasm for IAC was tempered by complications, including third cranial 
nerve palsy, orbital oedema, vitreous haemorrhage, retinal pigment epithelium changes and permanent 
retinal detachment resulting with loss of vision.20,21 In addition there is wide variation between centres 
in the number of times the IAC is administered. There is a learning curve in being able to successfully 
cannulate the ophthalmic artery, which cannot be performed in neonates and very young babies. The 
involvement of anterior intraocular structures in eyes that had failed IAC as well as other treatments 
can be detected clinically and in higher rates on histopathologic analysis after enucleation.22 Since the 
trabecular meshwork is an outflow from the eye, this is considered a high-risk feature and requires 
adjuvant systemic chemotherapy after enucleation.  
One of the most difficult features of retinoblastoma is the control of vitreous seeding, with many eyes 
requiring EBRT or enucleation.23 Recent attempts have been made to inject chemotherapy drugs 
directly into the vitreous cavity. Previously this route of delivery was prohibited, due to the risk of 
retinoblastoma seeding outside the eye. However, Munier et al overcame this risk by describing a 
safety enhanced technique, where the intraocular pressure was lowered by paracentesis of the anterior 
chamber, the intravitreal chemotherapy injection delivered by a 32G needle given in a tumour free 
area – confirmed via ultrasound biomicroscopy, and cryotherapy applied at the needle entry point as it 
was removed from the eye.24 In 2014, Munier further described the phenotypic variability of 
retinoblastoma seeds and classified them into 3 subtypes, namely dust, spheres and clouds.25 The 
vitreous seed classification can be predictive in regard to time to regression and number of intravitreal 
melphalan injections required: median time to regression was 0.6, 1.7, and 7.7 months for dust, 
spheres, and clouds, respectively, and median number of injections required to reach regression was 3, 
5, and 8 injections, respectively.26 In terms of tumour spread, Smith and Smith performed a systematic 
review in which they included 14 studies and more than 1,300 intravitreal injections, and concluded it 
is a rare occurrence.27  
Discussion  
During the last half century, the management of retinoblastoma has been revolutionized with the 
advent of novel therapeutic modalities. The shift from EBRT to systemic chemotherapy improved 
survival. The further shift to intraophthalmic artery and more recently the intravitreal delivery of 
chemotherapy has allowed eyes and vision to be retained that would otherwise be lost. Until the long-
term efficacy, side effect profile and spectrum of benefits are understood, these should be used with 
caution. Enucleation remains an important treatment for advanced cases, in which attempts to salvage 
the eye might pose the patient to risk of metastasis and death. The need for international multi-
institutional prospective studies to better define indications and complication profiles is self-evident in 
this rare but important cancer (ClinicalTrials.gov Identifier: NCT02097134 and NCT00335738). 
 
Uveal melanoma 
Introduction 
Among all melanoma cases, only 5% arise from the ocular and adnexal structures. Uveal melanoma is 
the most common primary intraocular malignancy in adults, occurring in approximately 6 individuals 
per million population annually.28 Of these, 5% originate from the iris, 10% from the ciliary body, and 
the majority, 85%, are choroidal (figure 2). Uveal melanoma mainly affects light-skinned individuals, 
though it can occur less frequently in dark-skinned. There is a slight male preponderance. It is 
considered to be a sporadic event, although associated with dysplastic naevus syndrome and ocular 
melanocytosis.  
Historically, uveal melanoma was treated by primary enucleation. However with advances in 
radiation delivery most centres now use radiotherapy by proton beam or plaque brachytherapy if 
tumour size allows, with high local tumour control rates and more than 90% eyes salvaged.29 
However vision is often compromised or lost due to radiation damage to the retina and optic nerve. A 
more exploratory treatment for small uveal melanoma is photodynamic therapy (low frequency 
laser),30 a modality under debate, not universally accepted, and which awaits long-term results.  
Uveal melanoma metastasizes via haematogenous spread primarily to the liver, and is believed to 
occur early in the course of the disease, despite successful treatment of the eye.31 In a retrospective 
analysis by Shields et al. of more than 8,000 patients, 33% and 25% of ciliary body and choroidal 
melanoma patients, respectively, were diagnosed with metastatic spread at 10 years.32 Iris melanoma 
had a more favourable prognosis. Size of the primary tumour at time of detection was important in 
determining the chances for secondary spread: at 10 years, metastasis were diagnosed in 12% of small 
melanoma (elevation ≤3.0mm), 26% of medium melanoma (elevation 3.1-8.0mm) and 49% of large 
melanoma (elevation >8.0mm).  
Despite the improvements in treatment of the primary tumour, a corresponding decrease in metastatic 
death has not been documented, with5-year relative survival rate of 70-80%.33,34 To date, metastatic 
uveal melanoma is a major challenge for physicians to treat although many new targeted immune 
modulatory treatments are now available such as PD1 inhibitors and MEK inhibitors in addition to 
targeted hepatic chemotherapy.   
Prognostic factors  
Several clinical and histopathological variables of primary uveal melanoma were found to be 
associated with metastatic death.35 These include increasing patient age, increasing tumour size 
(tumour elevation and independently tumour diameter), ciliary body involvement, extraocular 
extension, epithelioid cell type, lymphocytic infiltration, presence of fibrovascular loops and several 
biomarkers, including human leukocyte antigen (HLA) molecules, and others, by 
immunohistochemical methods. Some variables are used in practice more than others. However, 
advances over the past two decades have expanded our understanding of the molecular biology of the 
disease, and genetic studies more accurately predict chances for metastatic disease.  
In 1996 Prescher et al., using karyotyping and genomic hybridization techniques, found that 
monosomy of chromosome 3 predicted mortality in greater than 50%, whereas disomy of 
chromosome 3 had 100% survival.36 Additional abnormalities were found in chromosomes 8, 6 and 1, 
but loss of chromosome 3 and increased tumour size were found to be the most significant predictors 
of patient survival.37 Further studies with more advanced techniques confirmed these findings – 
Damato et al., using multiplex ligation-dependent probe amplification to detect chromosomal 
abnormalities, found that ten-year disease-specific mortality was 0% in tumours with disomy 3, 55% 
in tumours with monosomy 3, and 71% in tumours showing chromosome 3 loss and 8q gain.38 Later, 
using oligonucleotide microarrays, Tschentscher et al. determined gene expression levels in 20 uveal 
melanoma tumours and concluded that there are two distinct entities, or classes, of uveal melanoma, 
that correlate one to monosomy and the other to disomy 3.39 Onken and colleagues used hierarchical 
cluster analysis of gene expression and demonstrated that class 1 lesions have better prognosis and are 
associated with disomy 3 and a gain of chromosome 6p, whereas class 2 lesions predict more likely 
melanoma-related mortality and are associated with a loss of heterozygosity of chromosome 3.40 
Recently, Walter et al. found that class 2 uveal melanomas had better prognosis when the largest basal 
tumour diameter was less than 12mm at the time of treatment.41 Nearly all uveal melanomas harbour 
oncogenic mutations in the Gaq stimulatory subunit GNAQ.42	Harbour et al. found that mutations in 
BAP1, encoded by a gene on chromosome 3p21, and which is important for tumour suppression, were 
associated with increased risk of distant metastatis.43  
From a clinical perspective, tumour aspirates for genetic analysis are taken prior to plaque or proton 
beam radiotherapy or after eye removal. Patients found at high risk for systemic spread are considered 
candidates for intensive screening and for adjuvant targeted molecular therapy, currently under 
investigations in clinical trials.44  
Surveillance and treatments for metastatic disease 
Rarely in patients with uveal melanoma is metastatic spread detected concurrently with the diagnosis 
of the ocular tumour. Despite being treated for their primary tumour, these patients are at lifetime risk 
of developing metastasis. The role of screening tests for distant disease remains controversial within 
the ophthalmic and oncologic communities, as there is no serum biomarker that can be utilised and the 
evidence for imaging modality and frequency is conflicting. While some investigators advocate the 
use of screening tests for metastatic spread once every 4-6 months,31 others, relying on findings that 
early detection of metastatic disease is not associated with better survival rates,45 are reluctant to 
perform any tests whatsoever.  
Commonly used imaging techniques to detect distant spread, mainly to the liver, are ultrasonography, 
computed tomography (CT), positron emission tomography/CT (PET/CT) and magnetic resonance 
imaging (MRI). The National Guidelines for the Management of Uveal Melanoma in the UK state 
that all patients should be offered metastatic surveillance with non-ionising imaging of the liver 
(ultrasound or MRI) to prevent unnecessary radiation of the patient.46 Marshall et al. in a prospective 
study in 188 high risk uveal melanoma patients found that, by performing biannual MRI liver scans, 
92% of metastatic patients were diagnosed by imaging 6 months prior to experiencing any 
symptoms.47 In a comparative study, Orcurto and colleagues found that MRI is superior to PET/CT in 
detecting early hepatic metastasis, however PET/CT has a possible role in assessing early therapy 
response.48 Liver function tests, which were commonly used as a screening tool in the past, are often 
normal when liver metastasis are found early, and are considered an inadequate tool for surveillance 
when used alone.46  
Given that insulin-like growth factor-1 (IGF-1) receptor has been found to be highly expressed in 
metastatic uveal melanoma, Frenkel et al. assessed the role of serum IGF-1 in early diagnosis of uveal 
melanoma liver metastasis using enzyme-linked immunosorbent assays (ELISA) in 118 patients. This 
study revealed that serial IGF-1 measurements in 10-years' disease free patients were considerably 
lower compared to those in healthy controls, and higher compared to those with metastatic disease. 
The authors concluded that serial IGF-1 levels may have a role as a predictive biomarker for 
metastatic uveal melanoma when measured repeatedly in one individual.49 Triozzi et al. studied 76 
treated primary uveal melanoma patients and found a correlation between the presence of monosomy 
3 and human leukocyte antigen-class-I-associated β-2 microglobulin (P≤0.02). Based on the strong 
association between monosomy 3 and development of metastatic disease, the authors concluded that 
the microglobulin may have a potential role as a screening tool for metastatic disease.50  
Treatment options for metastatic uveal melanoma are limited. Surgical resection is considered the 
main strategy for a very highly selected population of patients with resectable disease.51 Other 
modalities, including chemo-embolization, radio-embolization and administration of classic 
chemotherapeutic agents, have shown limited efficacy, if at all.52 In the absence of classical 
modalities for metastatic disease, newly developed therapies have evolved lately, namely kinase 
inhibitors and immunotherapy, and these are currently evaluated.53,54 In this regard, selumetinib, a 
selective kinase inhibitor, was found in a randomized clinical trial to improve progression-free 
survival and response rate in metastatic uveal melanoma patients, as compared to chemotherapy.55 
Interestingly, in this study, no improvement in overall survival was observed.  
 
Discussion  
For more than three decades eye preserving plaque radiotherapy is the mainstay treatment for primary 
uveal melanoma with high eye salvage rate in long-term follow-up. Although exceptions exist, 
overall, local tumour control is no longer a major concern, but future metastatic risk after eye 
treatment remains a challenge. Most centres now offer earlier treatment, when a melanocytic lesion 
starts to develop suspicious features rather than wait for growth in such lesions. In the past two 
decades a rapid evolution in our understanding of the molecular behaviour of uveal melanoma has 
occurred, resulting in the development of more accurate genetic prognostic tools to detect patients at 
high risk for metastatic spread. The main focus is currently on the development of immune 
modulatory therapy for established metastatic disease. Once the optimum treatment for metastatic 
disease is developed we will have an effective therapy to use in the adjuvant setting, which will lead 
to improved survival.  
 
Conjunctival melanoma 
Introduction 
Conjunctival melanoma is an ocular surface cancer, and as so, it differs substantially in its features 
and management from the previously described intraocular tumours. It is a rare malignancy, 
accounting for 1-2% of all ocular melanomas. However incidence seems to be on an upward trend, 
analogous to increased incidence seen in cutaneous melanoma. As in cutaneous melanoma, exposure 
to solar radiation is considered an important risk factor and a suggested causative link.56 Conjunctival 
melanoma most commonly appears in middle aged or elderly white individuals, but can occur in 
African or African-Americans as well. The majority of conjunctival melanoma cases (75%) arise from 
primary acquired melanosis (PAM) with atypical cells, 20% from a pre-existing conjunctival naevus 
and only 5% de novo. Higher incidence of the disease is seen in several systemic conditions, 
including familial atypical mole and melanoma syndrome, xeroderma pigmentosum and 
neurofibromatosis.  
Clinically, conjunctival melanoma appears as a fleshy, elevated lesion of variable pigmentation, 
commonly located on the nasal or temporal bulbar conjunctiva (Figure 3). Amelanotic or minimally 
pigmented conjunctival melanomas occur in approximately one fifth of cases.57 The lesion can be well 
circumscribed or diffuse, the latter more frequently seen in cases arising from PAM. It may extend 
towards the eyelid margin or be contiguous with an eyelid margin melanoma, the globe or the orbit. It 
may also extend into the lacrimal drainage system or nose following tumour seeding at time of 
primary surgical resection, giving rise to epistaxis or epiphora as presenting signs of nasolacrimal 
recurrence.58  
Diagnosis 
Full examination of the bulbar and tarsal conjunctiva is required. In addition, examination of the 
orbital rim is important because of the high rate of recurrence. If orbital involvement is suspected, 
imaging with CT or MRI is indicated. Occasionally, an intraocular melanoma with extraocular 
extension may have the appearance of a conjunctival melanoma, warranting detailed fundoscopy and 
ultrasonography. Regional lymphadenopathy can occur. Lymphatic spread to proximal nodes has been 
assessed with various approaches, including whole body PET/CT scan, MRI of the head and neck and 
ultrasonography and fine needle aspiration biopsy of suspicious lymph nodes. Micrometastatic disease 
to regional lymph nodes is accessed using sentinel lymph node biopsy (SLNB).59,60  
Management 
All lesions suspicious for conjunctival melanoma should be referred to a specialized centre, without 
undertaking an incisional biopsy, as this may shed malignant cells. Complete resection with clinically 
evident clear margins is necessary, which may include corneal alcohol epitheliectomy or for tumours 
fixed to the sclera, lamellar scleral dissection. Only the clear margins are surgically handled to avoid 
tumour seeding, resulting in the ‘no-touch’ technique. After the tumour resection, double or triple 
freeze-thaw cryotherapy is applied to clear margins to prevent recurrence. The conjunctival gap may 
be left to re-conjunctivalise, undergo primary closure or be lined with graft material (allograft from 
the fellow eye or amniotic membrane).  
In cases of incomplete excision, adjuvant treatment with plaque brachytherapy (strontium or 
ruthenium) or topical chemotherapy (mitomycin C drops 0.02% or 0.04% in various protocols) is 
warranted to reduce chances of recurrence.61 Strontium 90 beta radiotherapy application is a useful 
adjuvant treatment for incompletely excised conjunctival melanoma where the deep margin is 
involved.62 Alternatively some centres used custom designed radioactive iodine plaques. If the tumour 
is incompletely excised from the fornix or caruncular area, proton-beam radiotherapy may be 
administered.61 After local excision, close follow-up is advised and if local recurrence occurs, lesions 
should be re-excised. In advanced cases with extensive orbital involvement, exenteration of the orbital 
contents is necessary.63 
Sentinel lymph node biopsy  
Of the various ways to assess lymphadenopathy, SLNB has recently been under the spotlight.59 
Adapted from management of cutaneous melanoma, its use in the management of conjunctival 
melanoma is controversial.64 Although up to 50% of patients with systemic spread of the disease show 
regional lymph node involvement, no consensus exists as to when SLNB should be performed or in 
which patients. In addition, this modality has not been proven to improve patient survival. The 
technique of SLNB involves pre-operative scintigraphic mapping of the afferent lymphatics using 
radionuclide imaging, followed by intraoperative localization of the sentinel node by methylene blue 
dye and/or radioactive tracer detected by a hand-held gamma probe. The selected sentinel nodes are 
dissected and submitted for histopathologic evaluation. In cases of positive sentinel lymph node 
biopsies, further regional lymphadenectomy is warranted. In an 8 year prospective study of ocular 
adnexal melanoma patients performed by Savar et al., SLNB has shown benefit in cases of tumours of 
2 mm in thickness or more, but also in smaller tumours associated with ulceration.65 The authors 
showed a significant decrease in the rate of false negative readings in the second half of the study, 
implying that the technique requires expertise, gained in a relatively shallow learning curve. In a 
retrospective analysis by Cohen et al., the authors concluded that SLNB should be considered when 
tumours are ≥2 mm thick and in cases of non-limbal location of the conjunctival melanoma.66 
Prognosis 
Our ability to explore the prognostic measures and outcomes of conjunctival melanoma is limited by 
the tumour’s rarity. Nevertheless, existing figures point out that by 10 years up to 50% of patients will 
have experienced a local recurrence, with palpebral location of the primary lesion and excision 
without the use of adjuvant therapy, being significant risk factors.61,67 Shields et al. investigated the 
outcomes of nearly 400 cases of conjunctival melanoma and found that for patients in which the 
melanoma originated from PAM – the majority of cases, metastasis occurred in 19% and death in 5% 
in 5 years. However, for patients for whom the melanoma originated de-novo, 5-years’ outcomes were 
significantly worse: 35% melanoma related-metastases and 17% deaths. At 10 years, more than one 
third of patients have died. On a multivariate analysis, melanoma arising de-novo, in contrast to that 
originating from PAM or pre-existing naevus, indeed was found to be a significant risk factor for the 
development of metastatic disease and death.57  
Genetic studies 
As for uveal melanoma, genetic studies have shed new light on the molecular basis of conjunctival 
melanoma. BRAF is a gene encoding to serine/threonine kinase mitogen-activated protein kinase 
(MAPK) pathway, which is involved in signal transduction. Mutations in BRAF were found in the 
majority of cutaneous melanoma, not at all in uveal melanoma, and in up to 50% of conjunctival 
melanoma.68 Additional studies to characterize and understand the role of BRAF mutations, as well as 
other mutations, are currently underway.64 In a study by Lake et al. BRAF V600E gene mutations 
were found in 50% of conjunctival melanoma and 75% of metastatic conjunctival melanoma.69 
Vemurafenib, a BRAF kinase inhibitor, was found in a phase 3 randomized clinical trial to prolong 
survival in metastatic cutaneous melanoma patients, 70 and first reports of its clinical use in the 
context of conjunctival melanoma are now emerging.71  
Discussion  
Conjunctival melanoma is a rare but deadly ocular surface cancer. Since the tumour is on the ocular 
surface, it is picked up at a smaller size compare to intraocular melanoma and survival figures are 
better.  Primary treatment includes surgical excision and application of cryotherapy with additional 
adjuvant treatments in cases of incomplete excision. Assessment of regional lymphadenopathy is 
essential, as lymphatic spread of the tumour is relatively a common occurrence, although distal 
metastatic spread without regional lymph node involvement has been reported in 25% of cases.72 
Further studies are warranted to better delineate the indications for use, advantages and disadvantages 
of each screening method, and specifically that of SLNB. Genetic studies on the molecular basis of 
conjunctival melanoma, and specifically BRAF mutations, are evolving, and will with no doubt be 
part of decision making in management and treatment of conjunctival melanoma.  
 
 
Conclusion	
Ocular tumours, in contrast to the majority of ophthalmic diseases, pose a threat not only to vision, 
but also to the integrity of the globe and moreover to life. Immense effort has been put in recent years 
into more accurate diagnosis, selective management with better side effect profile and useful 
screening tests for early detection of systemic spread of the ocular malignancies. Whereas survival 
rate in retinoblastoma in developed countries is very high, the main challenge is currently to salvage 
those eyes with advanced tumours. In contrast, in uveal and conjunctival melanoma, the major tasks 
are to further improve effective systemic treatment for metastatic disease and explore the role of 
adjuvant therapy in order to lower the rate of metastatic spread and death.  
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Legends	
Figure 1.  
Fundus photographs of retinoblastoma tumour grouping according to the International Intraocular 
Retinoblastoma Classification,6 and response to treatment. (A) Group A eye – tumours <3mm 
(arrows) confined to the retina, ≥3mm away from the foveola. (B) Same eye as in figure 1A after laser 
diode treatment. (C) Group B eye – a foveal tumour>3mm. (D) Same eye as in figure 1C after 
treatment with systemic chemotherapy – the tumour has shrunk and formed into a calcified inactive 
mass. (E) Group C eye – a retinal tumour with adjacent subretinal seeds less than 3 mm from tumour 
(arrow). (F) Same eye as in figure 1E after treatment with systemic chemotherapy and diode laser to 
the subretinal seeds. (G) Group D eye – a retinal mass and total retinal detachment. Intraocular 
pressure in this eye was within normal limits. (H) Same eye as in figure 1G after treatment with 
systemic chemotherapy. (I) Group E eye – a massive intraocular tumour occupying most of the 
posterior chamber, resulting with elevated intraocular pressure and neovascularization of the iris. The 
eye was enucleated.  
Figure 2.  
 (A) Fundus photograph of a left eye choroidal melanoma. (B) Same eye 2 years after treatment with 
plaque radiotherapy – tumour significantly decreased in size (note chorioretinal atrophy surrounding 
the tumour).  
Figure 3.  
(A) Slitlamp photograph of a conjunctival melanoma (resected and confirmed on histopathological 
evaluation) encroaching the limbus and cornea. (B) Same eye after surgical resection, alcohol 
epitheliectomy and cryotherapy to conjunctival margins.  
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required a reclassiﬁcation of intraocular disease
from the Reese-Ellsworth classiﬁcation,5 which
predicted the globe salvage after EBRT to the
International Intraocular Retinoblastoma Classiﬁcation
(IIRC), which was more relevant to chemotherapy
outcomes.6 Eyes manifesting the tumour were clas-
siﬁed into ﬁve groups from A to E (Fig. 1) accord-
ing to size, presence and extent of tumour seeds
(vitreous or subretinal), and development of sec-
ondary complications (e.g. neovascular glaucoma).
The disadvantages have included the inability to
use historical EBRT outcomes to compare against
emerging treatments and the fact that several ver-
sions of the IIRC have emerged. There is some
variation in the deﬁnition of tumours in Groups B
and C, but mainly in respect to Groups D and E
eyes.7 These discrepancies were thought to affect
the prognostic value of the IIRC, leading to both
over- and undertreatment.8
Management
IIRC Group A eyes are often amenable to treatment
by focal methods, such as cryotherapy or laser
Fig. 1 Fundus photographs of retinoblastoma tumour grouping according to the IIRC,6 and response to treatment. (A) Group A
eye—tumours <3mm (arrows) conﬁned to the retina, ≥3mm away from the foveola. (B) Same eye as in Figure 1A after laser
diode treatment. (C) Group B eye—a foveal tumour >3mm. (D) Same eye as in Figure 1C after treatment with systemic
chemotherapy—the tumour has shrunk and formed into a calciﬁed inactive mass. (E) Group C eye—a retinal tumour with
adjacent subretinal seeds <3mm from tumour (arrow). (F) Same eye as in Figure 1E after treatment with systemic chemo-
therapy and diode laser to the subretinal seeds. (G) Group D eye—a retinal mass and total retinal detachment. Intraocular
pressure in this eye was within normal limits. (H) Same eye as in Figure 1G after treatment with systemic chemotherapy.
(I) Group E eye—a massive intraocular tumour occupying most of the posterior chamber, resulting with elevated intraocular
pressure and neovascularization of the iris. The eye was enucleated.
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drugs directly into the vitreous cavity. Previously this
route of delivery was prohibited, due to the risk of
retinoblastoma seeding outside the eye. However,
Munier et al. overcame this risk by describing a
safety enhanced technique, where the intraocular
pressure was lowered by paracentesis of the anterior
chamber, the intravitreal chemotherapy injection
delivered by a 32G needle given in a tumour-free
area—conﬁrmed via ultrasound biomicroscopy, and
cryotherapy applied at the needle entry point as it
was removed from the eye.24 In 2014, Munier fur-
ther described the phenotypic variability of retino-
blastoma seeds and classiﬁed them into three
subtypes, namely dust, spheres and clouds.25 The vit-
reous seed classiﬁcation can be predictive in regard
to time to regression and number of intravitreal mel-
phalan injections required: median time to regression
was 0.6, 1.7 and 7.7 months for dust, spheres and
clouds, respectively, and median number of injec-
tions required to reach regression was 3, 5 and 8
injections, respectively.26 In terms of tumour spread,
Smith and Smith performed a systematic review in
which they included 14 studies and more than 1300
intravitreal injections, and concluded it is a rare
occurrence.27
Discussion
During the last half century, the management of ret-
inoblastoma has been revolutionized with the advent
of novel therapeutic modalities. The shift from EBRT
to systemic chemotherapy improved survival. The fur-
ther shift to intraophthalmic artery and more recently
the intravitreal delivery of chemotherapy has allowed
eyes and vision to be retained that would otherwise
be lost. Until the long-term efﬁcacy, side effect proﬁle
and spectrum of beneﬁts are understood, these should
be used with caution. Enucleation remains an import-
ant treatment for advanced cases, in which attempts
to salvage the eye might pose the patient to risk of
metastasis and death. The need for international
multi-institutional prospective studies to better deﬁne
indications and complication proﬁles is self-evident in
this rare but important cancer (ClinicalTrials.gov
Identiﬁer: NCT02097134 and NCT00335738).
Uveal melanoma
Introduction
Among all melanoma cases, only 5% arise from the
ocular and adnexal structures. Uveal melanoma is
the most common primary intraocular malignancy
in adults, occurring in approximately six indivi-
duals per million population annually.28 Of these,
5% originate from the iris, 10% from the ciliary
body and the majority, 85%, are choroidal (Fig. 2).
Uveal melanoma mainly affects light-skinned indivi-
duals, though it can occur less frequently in dark-
skinned. There is a slight male preponderance. It is
considered to be a sporadic event, although asso-
ciated with dysplastic naevus syndrome and ocular
melanocytosis.
Historically, uveal melanoma was treated by pri-
mary enucleation. However, with advances in radi-
ation delivery most centres now use radiotherapy
Fig. 2 (A) Fundus photograph of a left eye choroidal melanoma. (B) Same eye 2
years after treatment with plaque radiotherapy—tumour signiﬁcantly decreased in
size (note chorioretinal atrophy surrounding the tumour).
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local tumour control is no longer a major concern,
but future metastatic risk after eye treatment
remains a challenge. Most centres now offer earlier
treatment, when a melanocytic lesion starts to
develop suspicious features rather than wait for
growth in such lesions. In the past two decades a
rapid evolution in our understanding of the molecu-
lar behaviour of uveal melanoma has occurred,
resulting in the development of more accurate gen-
etic prognostic tools to detect patients at high risk
for metastatic spread. The main focus is currently
on the development of immune modulatory therapy
for established metastatic disease. Once the opti-
mum treatment for metastatic disease is developed
we will have an effective therapy to use in the adju-
vant setting, which will lead to improved survival.
Conjunctival melanoma
Introduction
Conjunctival melanoma is an ocular surface cancer,
and as so, it differs substantially in its features and
management from the previously described intraocu-
lar tumours. It is a rare malignancy, accounting for
1–2% of all ocular melanomas. However, the inci-
dence seems to be on an upward trend, analogous to
increased incidence seen in cutaneous melanoma. As
in cutaneous melanoma, exposure to solar radiation
is considered an important risk factor and a sug-
gested causative link.56 Conjunctival melanoma most
commonly appears in middle aged or elderly white
individuals, but can occur in African or African-
Americans as well. The majority of conjunctival
melanoma cases (75%) arise from primary acquired
melanosis (PAM) with atypical cells, 20% from a
pre-existing conjunctival naevus and only 5% de
novo. Higher incidence of the disease is seen in sev-
eral systemic conditions, including familial atypical
mole and melanoma syndrome, xeroderma pigment-
osum and neuroﬁbromatosis.
Clinically, conjunctival melanoma appears as a
ﬂeshy, elevated lesion of variable pigmentation, com-
monly located on the nasal or temporal bulbar con-
junctiva (Fig. 3). Amelanotic or minimally pigmented
conjunctival melanomas occur in approximately one
ﬁfth of cases.57 The lesion can be well circumscribed
or diffused, the latter more frequently seen in cases
arising from PAM. It may extend towards the eyelid
margin or be contiguous with an eyelid margin mel-
anoma, the globe or the orbit. It may also extend
into the lacrimal drainage system or nose following
tumour seeding at time of primary surgical resection,
giving rise to epistaxis or epiphora as presenting
signs of nasolacrimal recurrence.58
Diagnosis
Full examination of the bulbar and tarsal conjunc-
tiva is required. In addition, examination of the
orbital rim is important because of the high rate of
recurrence. If orbital involvement is suspected,
imaging with CT or MRI is indicated. Occasionally,
an intraocular melanoma with extraocular exten-
sion may have the appearance of a conjunctival
melanoma, warranting detailed fundoscopy and
ultrasonography. Regional lymphadenopathy can
occur. Lymphatic spread to proximal nodes has
Fig. 3 (A) Slitlamp photograph of a conjunctival melanoma (resected and conﬁrmed
on histopathological evaluation) encroaching the limbus and cornea. (B) Same eye
after surgical resection, alcohol epitheliectomy and cryotherapy to conjunctival
margins.
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